INS and type 2 diabetes mellitus: In accordance with data obtained by studies in rodents [190, 191], Pirro et al. observed that tirzepatide reduced circulating BCAA in patients with T2D, and this effect was strongly associated with biomarkers indicative of enhanced insulin sensitivity [200].